Display Settings:

Format

Send to:

Choose Destination
    Hum Vaccin. 2009 Mar;5(3):141-50. Epub 2009 Mar 14.

    Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study.

    Source

    Juvaris BioTherapeutics, Inc., Burlingame, CA, USA.

    Abstract

    This pilot study tested the immunogenicity of a novel cationic liposome-DNA complex (CLDC) immunomodulatory vaccine adjuvant. Combined with a specific antigen, CLDC enhanced anti-SIV immune responses induced by various SIV vaccine candidates. Rhesus macaques immunized in the presence of CLDC developed stronger SIV-specific T and B cell responses compared to animals immunized without CLDC. These differences persisted and resulted in better memory responses after an in vivo boost of the animals several months later with whole AT-2 inactivated SIVmac239. Thus, CLDC should be explored further as a potential immunomodulatory adjuvant in HIV vaccine design.

    PMID:
    18690014
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2728146
    Free PMC Article

    Images from this publication.See all images (9) Free text

    Figure 1
    Figure 3
    Figure 5
    Figure 7
    Figure 9
    Figure 2
    Figure 4
    Figure 6
    Figure 8

      Supplemental Content

      Icon for Landes Bioscience Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk